Amgen, Inc. http://www.alacrastore.com/company-snapshot/Amgen_Inc-1000953 Saturday, August 30, 2008 3:33:30 AM 1000953 Amgen, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/MW-0001-27697779newstex/MW-0001-27697779xml SOUTH SAN FRANCISCO, CA, Aug. ##, #### (Marketwire delivered by Newstex) -- SOUTH SAN FRANCISCO, CA -- (Marketwire) -- ##/##/## -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced the completion of a protocol-defined interim analysis...0700000007005000110000001100200004000000040020000400200607014000070140090701401207003000070030010700100007001005070010041300000013001000130010020200000002002000020020078/27/2008 8:21:52 AM1800000018022000180200001900000019002000190020071900100019001005MarketwireMW-0001-27697779AMGEN INCCYTOKINETICS INCANDREW A WOLFFAMGNCYTKNewsNewstexhttp://www.alacrastore.com/storecontent/spcred/665042spcred/665042normThe latest News from S&Pglobalstructured8/13/2008 6:40:00 PM100News665042United StatesBiotechnologyUnited StatesAsiaEmerging MarketsLatin AmericaGlobal IssuersStructured FinanceCorporationsAsset-Backed SecuritiesHealth CareConsumer ProductsNewsNEW YORK (Standard&Poor's) Aug. 13, 2008--Standard&Poor's Ratings Services said today that it revised its outlook on Thousand Oaks, Calif.-based Amgen Inc. to stable from negative. At the same time, Standard&Poor's affirmed its 'A+' corporate credit and senior unsecured debt ratings on the biotech company. "The actions are based on the continued strength of the company's drug portfolio and our belief that the sales drop in Amgen's flagship franchise, Aranesp/Epogen, is moderating," said Standard&Poor's credit analyst Arthur Wong. "The investment-grade ratings on Amgen Inc. reflect the company's strong business profile, highlighted by its high-margin product portfolio and improving pipeline, its robust free cash flows, and continued conservative financial policies," Mr. Wong added. "TheseUSA03116A03116B03116E03116C03116D03116203116J35201010 352010 3520 35Amgen Inc.118574USAASIAEMERGINGLATAMERICAAMGNNEWSGLOBISSSTRUCCORPABSHealthConsumerCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/665043spcred/665043normThe latest Research Update from S&Pglobalstructured8/13/2008 6:40:00 PM175Research Update665043United StatesBiotechnologyUnited StatesAsiaEmerging MarketsLatin AmericaGlobal IssuersStructured FinanceCorporationsAsset-Backed SecuritiesHealth CareConsumer ProductsResearch UpdateOn Aug. 13, 2008, Standard&Poor's Ratings Services revised its outlook on Thousand Oaks, Calif.-based Amgen Inc. to stable from negative. At the same time, Standard&Poor's affirmed its 'A+' corporate credit and senior unsecured debt ratings on the biotech company. The actions are based on the continued strength of the company's drug portfolio and our belief that the sales drop in Amgen's flagship franchise, Aranesp/Epogen, is moderating. The investment-grade ratings on Amgen Inc. reflect the company's strong business profile, highlighted by its high-margin product portfolio and improving pipeline, its robust free cash flows, and continued conservative financial policies. These factors are slightly offset by Amgen's challenges in generating sales growth and expanding its still relatively narrow drugUSA03116A03116B03116E03116C03116D03116203116J35201010 352010 3520 35Amgen Inc.118574USAASIAEMERGINGLATAMERICAAMGNRESUPDGLOBISSSTRUCCORPABSHealthConsumerCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/newstex/XIN-0001-27382456newstex/XIN-0001-27382456xml LOS ANGELES, Aug. ##, #### (Xinhua News Agency delivered by Newstex) -- Genentech (NYSE:DNA) rejected on Wednesday a ##-billion-dollar bid by Roche of Switzerland to take complete control of the San Francisco-based biotechnology company.Genentech...0400000004002000040020018/13/2008 2:20:13 PM1800000018016000English News ServiceXIN-0001-27382456AMGEN INCGENENTECH INCCHARLES A SANDERSAMGNDNANewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-27372982newstex/PRN-0005-27372982xml SEATTLE, Aug. ##, #### (PRNewswire delivered by Newstex) -- Omeros Corporation has announced the appointment of David A. Mann to the Company's Board of Directors. Mr. Mann also serves as Chairman of the Board's audit committee."Dave's...0900000009015000070000000700500004000000040020000400200604016000040160081300000013001000130010028/13/2008 9:22:08 AM1800000018007000PR Newswire USPRN-0005-27372982AMGEN INCOMEROS CORPTRUBION PHARMACEUTICALS INCDavid A MannAMGNOMERTRBNNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-27172655newstex/BW-0001-27172655xml Aug. #, #### (Business Wire) -- Research and Markets (http://www.researchandmarkets.com/research/#b####/amgen_partnering_g) has announced the addition of the "Amgen Partnering Guide ####" company profile to their offering. This report...040000000401800004016000040160138/5/2008 9:21:04 AM180000001801500018022000Business WireBW-0001-27172655AMGEN INCAMGNNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26999966newstex/PRN-0005-26999966xml MONTVALE, N.J., Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Amgen...07000000070130000400000004002000040020060401600004016031040160050701400007014012070030000700300102000000020020000200200802002006020020041300000013010000130100057/29/2008 10:20:33 AM1800000018020000180180001900000019001000PR Newswire USPRN-0005-26999966AMGEN INCBARR PHARMACEUTICALS INCNPS PHARMACEUTICALS INCAMGNBRLNPSPNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1880818ccbn/B1880818norm...New revenue and earnings guidance range suggest strong possibility Co. will actually grow in #### vs. ####.... 7/28/2008 11:52:00 PMAmgen54.0000EditedAmgen Q2 2008 Earnings Conference Call SummaryAMGN5:00pm ETBriefB1880818Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1880818ccbn/T1880818norm...My name is Dennis, and I will be your conference facilitator today for Amgen's second quarter #### financial results conference call. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q&A session. (OPERATOR INSTRUCTIONS) I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin. ... 7/28/2008 6:06:00 PMAmgen54.0000FinalAmgen Q2 2008 Earnings Conference Call TranscriptAMGN5:00pm ETTranscriptT1880818Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/CCN-0001-26960965newstex/CCN-0001-26960965xml GENEVA, SWITZERLAND, Jul. ##, #### (Marketwire delivered by Newstex) -- Addex Pharmaceuticals is pleased to announce the appointment of Laurent Galibert to its executive management team, as head of the Addex Inflammation Business Unit.Vincent...070000000700500004000000040020000400200607014000070140120701401907003000070030011300000013010000130100057/28/2008 2:21:16 AM1800000018018000Marketwire CanadaCCN-0001-26960965AMGEN INCLIGAND PHARMACEUTICALS INCMERCK & CO INCAMGNLGNDMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-26960932newstex/MW-0001-26960932xml GENEVA, SWITZERLAND, Jul. ##, #### (Marketwire delivered by Newstex) -- GENEVA, SWITZERLAND -- (MARKET WIRE) -- ##/##/## -- Addex Pharmaceuticals is pleased to announce the appointment of Laurent Galibert to its executive management...070000000700500004000000040020000400200607014000070140120701401907003000070030011300000013010000130100057/28/2008 2:21:16 AM1800000018018000MarketwireMW-0001-26960932AMGEN INCLIGAND PHARMACEUTICALS INCMERCK & CO INCAMGNLGNDMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/HUG-0001-26960481newstex/HUG-0001-26960481xml Jul. ##, #### (Hugin AS delivered by Newstex) -- FranA§ais (PDF) Deutsch (PDF) English (PDF) Geneva, Switzerland, ## July #### - Addex Pharmaceuticals is pleased to announce the appointment of Laurent Galibert to its executive...070000000700500004000000040020000400200607014000070140120701401907003000070030011300000013010000130100057/28/2008 1:17:15 AM1800000018018000Hugin ASHUG-0001-26960481AMGEN INCLIGAND PHARMACEUTICALS INCMERCK & CO INCAMGNLGNDMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26830758newstex/PRN-0005-26830758xml RICHMOND, Va., Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Insmed Inc. (Nasdaq CM: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present...0700000007005000040000000400200004002006040160000401603107003000070030011300000013010000130100050200000002002000020020087/22/2008 9:21:01 AM180000001801800018020000PR Newswire USPRN-0005-26830758AMGEN INCINSMED INCGEOFFREY ALLANAMGNINSMNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-26743487newstex/BW-0001-26743487xml Jul. ##, #### (Business Wire) -- Amgen (NASDAQ:AMGN) today announced that it plans to report its second quarter financial results on Monday, July ##, #### after the close of the financial markets. The announcement will be followed...040000000401600004016048040160187/17/2008 5:20:13 PM180000001800800018004000Business WireBW-0001-26743487AMGEN INCKEVIN W SHARERAMGNNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-26509338newstex/MW-0001-26509338xml LOS ANGELES, CA, Jul. #, #### (Marketwire delivered by Newstex) -- LOS ANGELES, CA -- (MARKET WIRE) -- ##/##/## -- Mitratech, a leading provider of software solutions for organizations to manage legal, compliance, and security risks,...0200000002002000020020060400000004016000040160277/8/2008 10:18:04 AM180000001800200018014000190000001900100019001005MarketwireMW-0001-26509338AMGEN INCHALLIBURTON COAMGNHALNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-26078492newstex/BW-0001-26078492xml Jun. ##, #### (Business Wire) -- Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today issued the following statement on the outcome of todaya€™s meeting of the U.S. Food and Drug Administrationa€™s...070000000701300007005000040000000400200004002006040060000400600504016000040160010401600307014000070140060701401207014001070140170701400207003000070030010701100007011003070010000700100413000000130010001300100213010000130100050200000002002000020020040200200602002008140000001402400014024001080030006/18/2008 6:15:27 PM1800000018020000180080001801800018006000180140001900000019001000Business WireBW-0001-26078492AMGEN INCWYETHWYETH $2 CONVERTIBLEAMGNWYEWYE PRNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26065621newstex/PRN-0005-26065621xml BIRMINGHAM, Ala., Jun. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that William P. Sheridan, MB BS, has been appointed Chief Medical Officer of BioCryst, effective...07000000070050000400000004002000040020060701400007014012070140081300000013010000130100056/18/2008 9:26:12 AM180000001802000018007000PR Newswire USPRN-0005-26065621AMGEN INCBIOCRYST PHARMACEUTICALS INCJon P StonehouseAMGNBCRXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26062510newstex/PRN-0005-26062510xml ROCKVILLE, Md., Jun. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today...0700000007005000090000000901500008000000080050000400000004002000040020060401600004016005040160080400600004006005070140000701400607014008070140170701401207001000070010040200000002002000020020061300000013002000130020056/18/2008 9:26:10 AM18000000180160001800700018020000PR Newswire USPRN-0005-26062510AMGEN INCENTREMED INCJames S BurnsAMGNENMDNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1869524ccbn/T1869524norm... - Goldman Sachs - AnalystGood morning. We're going to continue our presentation now with Amgen. This is obviously a company that doesn't require too much introduction. We are delighted this morning to have Jim Daly, who is the senior vice president for North America Commercial Operations presenting to us. On the podium is also Arvind Sood, who I think most of you know, who is the head of the Investor Relations department, and there are other teams, team members from his department here as well, but I'll leave it up to Arvind to introduce them if needed. But we're delighted that you're here and please proceed. ... 6/11/2008 4:05:00 PMAmgen54.0000FinalAmgen at Goldman Sachs Healthcare Conference TranscriptAMGN8:40am PTTranscriptT1869524Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/fitch/388942_report_framefitch/388942_report_framepdfFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Abbott LaboratoriesAmgen, Inc.AstraZeneca plcBristol-Myers Squibb CompanyEli Lilly & CompanyGlaxoSmithKline plcJohnson & JohnsonMerck & Company, Inc.Novartis AGPfizer Inc.Roche Deutschland Holding GmbHSanofi-Aventis S.A.Schering-Plough CorporationWyeth800917408036051680361372803614198036159280361630803624348041717980457972804579768045797980457983806562368071041080843884850944736/9/2008 10:11:00 AM0100000001030000010317000103170301040000275Special ReportABTAMGNAZNBMYGSKJNJLLYMRKNOVNPFESANSGPWYE388942_report_frameCredit & Investment ResearchFitchResearch